Sai Life Sciences Limited, a Contract Research, Development, and Manufacturing Organization (CRDMO), inaugurated a Peptide Research Center at its integrated R&D campus in Hyderabad, India.
Expanding Capabilities for Next-Generation Therapeutics
Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, highlighted, “As the pharmaceutical industry shifts from small molecules to emerging modalities like peptides, we are expanding our capabilities to stay ahead. Our new Peptide Research Center meets the growing demand for complex peptide synthesis and conjugation. This investment reinforces our role as a trusted partner in advancing next-generation therapeutics.”
Specialized Services and Advanced Technologies
The Peptide Research Center offers specialized support to pharma and biotech innovators by providing expertise in peptide synthesis, discovery, and complex conjugation. The facility features:
*Automation and advanced liquid handling systems
*Robotics and high-throughput platforms
*Scalable precision technologies for peptide-based drug development
Meeting the Rising Demand for Peptide Therapeutics
Maneesh Pingle, Head of Discovery Services, stated, “Peptide therapeutics are gaining momentum due to their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a highly experienced team delivering successful peptide discovery and development projects. With our expanded capabilities, we are well-positioned to support clients as they advance peptide therapies across various therapeutic areas.”
Integrated Approach for Seamless Drug Discovery
The Peptide Research Center seamlessly integrates with Sai Life Sciences’ end-to-end discovery services, including synthetic and medicinal chemistry, biology, DMPK, and toxicology. This holistic approach ensures smooth transitions across drug discovery stages, faster timelines, and higher success rates for peptide-based therapeutics.
Strengthening Global Partnerships in Peptide Innovation
Sai Life Sciences combines deep scientific expertise, cutting-edge technology, and an integrated approach. This reinforces its commitment to supporting global clients in developing innovative peptide therapeutics. As per the press release, the initiative strengthens the company’s position as a trusted partner in the evolving pharmaceutical landscape.
